Reporting Adverse Drug Reactions in India

Author: IQPC Middle East
Published: 2011/05/29 - Updated: 2022/03/21
Topic: India - Publications List

Page Content: Synopsis - Introduction - Main

Synopsis: Focusing the attention of the medical community on the importance of Indian adverse drug reporting to ensure maximum patient health in India.

The program is called the National Pharmacovigilance Program and it is funded by the WHO to foster the reporting culture in India and make sure that people are receiving safe medicine.

India is the world's second most populated country with over one billion potential drug consumers, and a value of US $1 billion worth of clinical trials, therefore it is very important to focus the attention of the medical community on the importance of the adverse drug reporting to ensure maximum patient health.

Introduction

Adverse Drug Reactions (ADRs) are the sixth global leading cause of death among hospitalized patients and the incidence of serious ADRs in hospitalized patients is 6.7 percent (Joshi et al).

Main Item

India is the world's second most populated country with over one billion potential drug consumers, and a value of US $1 billion worth of clinical trials, therefore it is very important to focus the attention of the medical community on the importance of the adverse drug reporting to ensure maximum patient health.

Dr. Viraj Suvarna, Medical Director at Boehringer Ingelheim who is speaking at the Pharmacovigilance India Summit has said that while multinational Pharmaceutical companies which operate in India clearly have very stringent adverse event reporting requirements, doctors are reluctant to report adverse events.

"Doctors in India don't really understand the difference between an adverse event and an adverse drug reaction. So they believe that they need to report only if that particular event has a causal relationship to that product in question. Despite the fact that we've trained so many doctors over so many years, one will still find them to be a little uneducated or a little hesitant to report because sometimes they feel that they could land into a medical-legal complication because once they report, then they think that that report will be processed and it could go against them", added Dr Suvarna.

This culture of reluctance in reporting is now changing as The Ministry of Health in India has launched a complete roadmap for a proactive pharmacovigilance system which will increase the awareness about the benefits of adverse event reporting.

This program is called the National Pharmacovigilance Program and it is funded by the WHO to foster the reporting culture in India and make sure that people are receiving safe medicine.

Pharmacovigilance India

This first edition of Pharmacovigilance India took place 27-29 June 2011 at the Hilton Mumbai International Airport and explored the National Pharmacovigilance Program in detail and provided an opportunity for industry stakeholders to meet, network, do business and share industry best-practices.

Pharmacovigilance India Summit features informative presentations and case-studies from high profile speakers, including Dr. Y. K. Gupta, National Coordinator of Pharmacovigilance Program of India and other key speakers from organizations such as International Society of Pharmacovigilance, UK, Bayer Healthcare Global R & D Center, China, Boehringer Ingelheim, Baxter Healthcare, Asia Pacific, Takeda Pharmaceuticals International, USA, Panacea Biotec, Wockhardt, Novartis Healthcare, Astellas Pharma, India, Bayer Healthcare, UCB, India, and Biocon, India.

Attribution/Source(s):
This quality-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its significant relevance to the disability community. Originally authored by IQPC Middle East, and published on 2011/05/29 (Edit Update: 2022/03/21), the content may have been edited for style, clarity, or brevity. For further details or clarifications, IQPC Middle East can be contacted at iqpc.com. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Similar Topics

- A multi-level, multi-stakeholder campaign to build awareness of disability issues, new law and support for inclusive and accessible Planet Earth.

- Disability Ethics research paper by Rev. S. Manohar Pradeep from Bangalore India regarding well being of persons with disability for moral theologians and ethicists.

Citing Information and Page References

Disabled World (DW) is a comprehensive online resource providing information and news related to disabilities, assistive technologies, and accessibility. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): IQPC Middle East. (2011, May 29 - Last revised: 2022, March 21). Reporting Adverse Drug Reactions in India. Disabled World (DW). Retrieved February 8, 2025 from www.disabled-world.com/news/asia/india/culture.php

Permalink: <a href="https://www.disabled-world.com/news/asia/india/culture.php">Reporting Adverse Drug Reactions in India</a>: Focusing the attention of the medical community on the importance of Indian adverse drug reporting to ensure maximum patient health in India.

While we strive to provide accurate and up-to-date information, it's important to note that our content is for general informational purposes only. We always recommend consulting qualified healthcare professionals for personalized medical advice. Any 3rd party offering or advertising does not constitute an endorsement.